Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers
A Double-blind, Comparative, Superiority, Multi-centre Investigation Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers
1 other identifier
interventional
201
4 countries
44
Brief Summary
Compare the efficacy of using an absorbent foam silver dressing (Mepilex Ag) versus the equivalent dressing without silver in subjects suffering from venous leg ulcer or mixed ulcer with an ABPI ≥ 0.8 and with inflammatory signs. Efficacy will be defined as absolute wound size reduction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Dec 2009
Longer than P75 for phase_4
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2009
CompletedFirst Submitted
Initial submission to the registry
December 18, 2009
CompletedFirst Posted
Study publicly available on registry
December 21, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedResults Posted
Study results publicly available
September 12, 2014
CompletedSeptember 12, 2014
December 1, 2013
3.8 years
December 18, 2009
September 4, 2014
September 11, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy Will be Defined as Absolute Wound Size Reduction.
Efficacy will be defined as absolute wound size reduction.
8 weeks
Secondary Outcomes (1)
Change in Inflammatory Signs
4 weeks
Study Arms (2)
Mepilex product
PLACEBO COMPARATORMepilex Ag
ACTIVE COMPARATORInterventions
Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
Eligibility Criteria
You may qualify if:
- Subjects with colonised/ local infection in a venous leg ulcer or mixed leg ulcer with an ABPI ≥ 0,8 and \< 1.3
- A history of an appropriate compression therapy for at least 2 weeks prior to randomisation
- Subjects with colonised/local infection presenting with three of five following specified signs:
- pain between dressing changes
- exuding wounds
- erythema on peri-wound skin
- oedema
- odour
- An ulcer size of at least 4 cm2 and a maximum size witch could be covered by one investigational product of 15x15 cm.
- Ulcer duration 6 weeks to 1 year
- In case of multiple ulcers: target ulcer must be at least 3 cm distant from other ulcers.
- Both gender with an age ≥ 18 years
- Signed informed consent
You may not qualify if:
- \> 10% necrotic (black) or fibrinous (yellow) tissue covering the wound bed
- Infected wounds in need of systemic antibiotic treatment
- Previous treatment with MepilexAg® on the target ulcer
- Use of systemic antibiotics for any reason during the previous 7 days
- Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer/malignancy and severe anaemia) judged by the investigator to be a potential interference in the wound evaluation
- Subjects with poorly controlled diabetes mellitus i.e. HbA1c \>8%
- Subjects treated with systemic immunosuppressive or glucocorticosteroids, except subjects taking occasional doses or doses less than 10mg prednisolon/day or equivalent. Subjects inhaling glucocorticosteroids for asthma should not be excluded.
- Known allergy/hypersensitivity to any of the components of the investigation products.
- Subjects with physical and/or mental conditions that are not expected to comply with the investigation due to poor medical condition
- Participation in other clinical investigation(s) within 1 month prior to start of the investigation.
- Previously randomised to this investigation.
- Life expectance of the subject less than 3 months
- Pregnant or breast-feeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (44)
Nemocnice Jihlava
Jihlava, Jihlava, 586 01, Czechia
Krajská nemocnice Liberec
Liberec, Liberec, 46063, Czechia
chirugické oddělení, Fakultní nemocnice Královské Vinohrady
Prague, Prague, 10 PSČ 100 34, Czechia
Nemocnice Podlesí a.s.
Třinec, Třinec, 73961, Czechia
Uherskohradišťská nemocnice a. s.
Uherské Hradiště, Uherské Hradiště, 68668, Czechia
Fakultní nemocnice U svate Anny, St. Anne´s University Hospital
Brno, 65691, Czechia
Dermatovenerologická klinika, University Hospital Bohunice,
Brno, Czechia
Dermatovenerologická klinike, Univerzita Karlova
Pilsen, 305 99, Czechia
Fakultní nemocnice Na Bulovce
Prague, 180 00, Czechia
Masarykova Hospital, Dermatology dept.
Ústí nad Labem, 401 13, Czechia
Dermatovenerologie Rendlová s.r.o.
České Budějovice, České Budějovice, 37001, Czechia
Polyclinique de Picardie Service d'Angiologie Phlébologie
Amiens, Amiens, 80000, France
Hôpital privé d'Antony Service de Dermatologie
Antony, Antony, 92160, France
Hôpital Saint Jacques - CHU Besançon
Besançon, Besançon, 25030, France
Résidence le Bristol
Boulogne-sur-Mer, Boulogne-sur-mer, 62200, France
CHU Le Bocage Service Dermatologie
Dijon, Dijon Cedex, 21079, France
Hôpital Albert Michallon Service de médecine vasculaire
Grenoble, Grenoble Cedex 9, 38 043, France
CHG La Roche-sur-Yon Service de D'Angiologie,Les Oudairies
La Roche-sur-Yon, La Roche-sur-Yon, 85925, France
Centre Hospitalier le Mans Service de Dermatologie
Le Mans, Le Mans Cedex 9, 72037, France
Pharmacie Centrale-Service Arsenal
Nantes, Nantes, 44093, France
APHP Hôpital Lariboisère
Paris, Paris, 75010, France
Hôpital Saint Joseph
Paris, Paris, 75014, France
Cabinet d'Angiologie, 1 bis rue de Salgareda
Saint-Alban, Saint Alban, 31140, France
Dermatology Department, University Hospital, Hopital Sud
Amiens, 80054, France
Service de Dermatologie, Centre Hospitalier Regional Universitaire
Caen, 140 33, France
Cabinet D'Angeiologie
Lille, 690 00, France
Hopital Maringer-Villemin- Fournier
Nancy, France
Hôpital Rotchild - Jean Rostand
Paris, 75012, France
Hopital Robert Debré Service de Dermatologie
Reims, France
Hopital Charles Nicolle
Rouen, France
Maison de Santé Protestante de Bordeaux-Bagatelle
Talence, France
Hopital Beauregard / Secrétariat de Dermatologie
Thionville, 57100, France
Service de dermatologie
Toulon, France
Clinique Pasteur
Toulouse, 31076, France
Universitätsklinikum Schleswig-Holstein Campus Lübeck
Lübeck, Germany, 23538, Germany
Universtätsmedizin Charité Klinik für Dermatologie, Allergologie und Venerologie
Berlin, 10117, Germany
Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken -
Bochum, 44805, Germany
Universitätsklinikum Hamburg-Eppedorf
Hamburg, 20246, Germany
Bramfelder Chaussee 200
Hamburg, 22177, Germany
Universität klinikum Jena, Klinik für dermatologie und dermatologische
Jena, 07740, Germany
University Hospital Regensburg
Regensburg, Germany
Universitäts-Hautklinik
Tübingen, 72076, Germany
Dermatology department
Amsterdam, 1081, Netherlands
St. Antonius Ziekenhuis
Utrecht, Netherlands
Results Point of Contact
- Title
- Ann Larkö
- Organization
- Molnlycke Health Care AB
Study Officials
- PRINCIPAL INVESTIGATOR
Sylvie Meaume, Dr
Hopital Rotchild - Jean Rostand, Paris
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- LTE60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 18, 2009
First Posted
December 21, 2009
Study Start
December 1, 2009
Primary Completion
October 1, 2013
Study Completion
October 1, 2013
Last Updated
September 12, 2014
Results First Posted
September 12, 2014
Record last verified: 2013-12